川能動力(000155.SZ):會東堵格一期風電場併網發電
格隆匯 9 月 25日丨川能動力(000155.SZ)公佈,公司所屬公司四川省能投會東新能源開發有限公司(“川能會東公司”)投資建設的會東堵格一期風電場全部風電機組於2020年9月24日成功併網發電。
會東堵格一期風電場項目總裝機容量100MW,主體工程由40台2500千瓦風力發電機組、40台箱式變壓器、5回35千伏集電線路及1座220千伏升壓站組成。根據可研設計數據,項目投產後預計年平均上網電量2.6億千瓦時,預計可實現年發電收入1.58億元(含税)。該項目併網發電將擴大公司風力發電規模,對公司未來業績產生積極影響。以上數據可能因為客觀因素的變化而產生偏差,敬請投資者謹慎決策、理性投資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.